AP2227A - 5,7-diaminopyrazolo [4,3-d]pyrimidines with PDE-5 inhibiting activity. - Google Patents

5,7-diaminopyrazolo [4,3-d]pyrimidines with PDE-5 inhibiting activity.

Info

Publication number: AP2227A
Authority: AP; ARIPO
Prior art keywords: diaminopyrazolo; pde; pyrimidines; inhibiting activity; inhibiting
Prior art date: 2003-11-24

Application number

AP2006003591A

Other languages

English (en)

Other versions

AP2006003591A0 (en

Inventor

Andrew Simon Bell

David Graham Brown

Kevin Neil Dack

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-24

Filing date

2004-11-12

Publication date

2011-03-29

2004-11-12 Application filed by Pfizer filed Critical Pfizer

2006-04-30 Publication of AP2006003591A0 publication Critical patent/AP2006003591A0/xx

2011-03-29 Application granted granted Critical

2011-03-29 Publication of AP2227A publication Critical patent/AP2227A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Immunology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AP2006003591A 2003-11-24 2004-11-12 5,7-diaminopyrazolo [4,3-d]pyrimidines with PDE-5 inhibiting activity. AP2227A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0327319.0A GB0327319D0 (en)	2003-11-24	2003-11-24	Novel pharmaceuticals
PCT/IB2004/003747 WO2005049616A1 (en)	2003-11-24	2004-11-12	5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY

Publications (2)

Publication Number	Publication Date
AP2006003591A0 AP2006003591A0 (en)	2006-04-30
AP2227A true AP2227A (en)	2011-03-29

Family

ID=29764364

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2006003591A AP2227A (en)	2003-11-24	2004-11-12	5,7-diaminopyrazolo [4,3-d]pyrimidines with PDE-5 inhibiting activity.

Country Status (43)

Country	Link
EP (1)	EP1689751B1 (is)
JP (1)	JP4056015B2 (is)
KR (2)	KR100848216B1 (is)
CN (4)	CN1882591B (is)
AP (1)	AP2227A (is)
AR (1)	AR046711A1 (is)
AT (1)	ATE485297T1 (is)
AU (1)	AU2004290643B2 (is)
BR (1)	BRPI0416869A (is)
CA (1)	CA2546987C (is)
CR (1)	CR8416A (is)
CY (1)	CY1110933T1 (is)
DE (1)	DE602004029705D1 (is)
DK (1)	DK1689751T3 (is)
EA (1)	EA011772B1 (is)
EC (1)	ECSP066580A (is)
ES (1)	ES2351622T3 (is)
GB (1)	GB0327319D0 (is)
GE (1)	GEP20084528B (is)
HR (1)	HRP20100651T1 (is)
IL (1)	IL175433A (is)
IS (1)	IS8406A (is)
MA (1)	MA28172A1 (is)
ME (1)	ME01216B (is)
MX (1)	MXPA06005914A (is)
MY (1)	MY140872A (is)
NL (1)	NL1027568C2 (is)
NO (1)	NO336526B1 (is)
NZ (1)	NZ548097A (is)
OA (1)	OA13289A (is)
PA (1)	PA8617701A1 (is)
PE (1)	PE20051061A1 (is)
PL (1)	PL1689751T3 (is)
PT (1)	PT1689751E (is)
RS (1)	RS51556B (is)
SG (1)	SG133614A1 (is)
SI (1)	SI1689751T1 (is)
TN (1)	TNSN06154A1 (is)
TW (1)	TWI265031B (is)
UA (1)	UA81994C2 (is)
UY (1)	UY28625A1 (is)
WO (1)	WO2005049616A1 (is)
ZA (1)	ZA200602899B (is)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2580856A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1804799B1 (en)	2004-09-20	2013-08-21	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101084212A (zh)	2004-09-20	2007-12-05	泽农医药公司	杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
CA2580845A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP1799667B1 (en)	2004-09-20	2013-03-20	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as therapeutic agents
CA2580855A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1830837B1 (en)	2004-09-20	2013-09-04	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
CA2585557C (en) *	2004-10-28	2009-08-18	Pharmacia & Upjohn Company Llc	Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors
BRPI0609225A2 (pt)	2005-05-12	2010-03-09	Pfizer	formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
MX2007015216A (es)	2005-06-03	2008-02-22	Xenon Pharmaceuticals Inc	Derivados de aminotiazol y sus usos como agentes terapeuticos.
NL1029244C2 (nl) *	2005-06-10	2006-12-12	Ronald Silfried Marlin	Middel ter vergroting van het mannelijk geslachtsorgaan.
DE102005050377A1 (de) *	2005-10-21	2007-04-26	Bayer Healthcare Ag	Heterocyclische Verbindungen und ihre Verwendung
NL2000291C2 (nl) *	2005-11-10	2009-02-17	Pfizer Prod Inc	1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
WO2007070872A1 (en)	2005-12-15	2007-06-21	Rigel Pharmaceuticals, Inc.	Kinase inhibitors and their uses
EP1820502A1 (en) *	2006-02-10	2007-08-22	Laboratorios Del Dr. Esteve, S.A.	Active substance combination comprising azolylcarbinol compounds
WO2007113243A2 (en) *	2006-03-31	2007-10-11	Investigación Y Clínica Andrológicas S.L.	Use of pde 5 inhibitors for the treatment of overactive bladder
WO2008132589A1 (en) *	2007-05-01	2008-11-06	Pfizer Limited	Combinations comprising pregabalin
WO2009050554A2 (en) *	2007-10-19	2009-04-23	Pfizer Inc.	Treatment of central nervous system disorders
DE102008063992A1 (de) *	2008-12-19	2010-09-02	Lerner, Zinoviy, Dipl.-Ing.	Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
ES2602794T3 (es)	2011-03-31	2017-02-22	Pfizer Inc	Piridinonas bicíclicas novedosas
WO2012172449A1 (en)	2011-06-13	2012-12-20	Pfizer Inc.	Lactams as beta secretase inhibitors
EP2751116B1 (en)	2011-08-31	2016-10-12	Pfizer Inc	Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
CA2872154C (en)	2012-05-04	2016-08-23	Pfizer Inc.	Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2
US9260455B2 (en)	2012-09-20	2016-02-16	Pfizer Inc.	Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk)	2012-09-21	2016-01-25	Пфайзер Інк.	Біциклічні піридинони
EP2931731A1 (en)	2012-12-11	2015-10-21	Pfizer Inc.	Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
US9403846B2 (en)	2012-12-19	2016-08-02	Pfizer Inc.	Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
CA2897678A1 (en)	2013-02-13	2014-08-21	Pfizer Inc.	Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en)	2013-02-15	2016-01-12	Pfizer Inc.	Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
MA38333A1 (fr)	2013-02-19	2017-02-28	Pfizer	Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
EP3052495B1 (en)	2013-10-04	2019-06-26	Pfizer Inc	Novel bicyclic pyridinones as gamma-secretase modulators
JP2017500333A (ja) *	2013-12-20	2017-01-05	バイエル・ファルマ・アクティエンゲゼルシャフト	グルコース輸送阻害剤
CN106211770B (zh)	2014-04-01	2018-02-06	辉瑞公司	作为γ‑分泌酶调节剂的色烯和1,1A,2,7B‑四氢环丙烷并[c]色烯吡啶并吡嗪二酮
PL3126354T3 (pl) *	2014-04-04	2020-06-15	H. Lundbeck A/S	Fluorowcowane chinazolino-THF-aminy jako inhibitory PDE1
CN106459088A (zh)	2014-04-10	2017-02-22	辉瑞公司	2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺
WO2016012896A1 (en)	2014-07-24	2016-01-28	Pfizer Inc.	Pyrazolopyrimidine compounds
SG11201700243YA (en)	2014-08-06	2017-02-27	Pfizer	Imidazopyridazine compounds
CA2963051C (en) *	2014-12-08	2023-10-17	Janssen Sciences Ireland Uc	Piperidine substituted pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (rsv)
BR112017015693A2 (pt)	2015-02-03	2018-03-20	Pfizer	ciclopropabenzofuranil piridopirazinadionas
DK3310784T3 (da)	2015-06-17	2020-11-09	Pfizer	Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
WO2017051294A1 (en)	2015-09-24	2017-03-30	Pfizer Inc.	N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
EP3353183A1 (en)	2015-09-24	2018-08-01	Pfizer Inc	N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3]thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl]amides
WO2017051303A1 (en)	2015-09-24	2017-03-30	Pfizer Inc.	Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
MX379704B (es)	2016-02-23	2025-03-11	Pfizer	Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
SG11201811712QA (en)	2016-07-01	2019-01-30	Pfizer	5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
PT3642202T (pt)	2017-06-22	2023-02-02	Pfizer	Derivados de dihidro-pirrolo-piridina
CA3094366A1 (en)	2018-03-23	2019-09-26	Pfizer Inc.	Piperazine azaspiro derivatives
EP3802540A1 (en)	2018-06-04	2021-04-14	Exscientia Ltd	Pyrazolopyrimidine compounds as adenosine receptor antagonists
TWI837169B (zh) *	2018-08-24	2024-04-01	美商拓臻股份有限公司	甲狀腺素受體β促效劑化合物
CN121081472A (zh)	2018-12-13	2025-12-09	拓臻股份有限公司	一种THRβ受体激动剂化合物及其制备方法和用途
AU2020336272A1 (en)	2019-08-23	2022-04-14	Terns Pharmaceuticals, Inc.	Thyroid hormone receptor beta agonist compounds
EP4028008A4 (en)	2019-09-12	2023-09-13	Terns Pharmaceuticals, Inc.	Thyroid hormone receptor beta agonist compounds
WO2021154668A1 (en) *	2020-01-27	2021-08-05	Bristol-Myers Squibb Company	1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
WO2022182658A1 (en)	2021-02-23	2022-09-01	Hoth Therapeutics, Inc.	Use of aprepitant for treating alzheimer's disease
JP7788056B2 (ja) *	2022-03-10	2025-12-18	積水化学工業株式会社	ウイルス感染阻止剤、ウイルス感染阻止製品、ウイルス感染阻止塗料及び樹脂組成物
WO2024118524A1 (en)	2022-11-28	2024-06-06	Cerevel Therapeutics, Llc	Azaindole compounds and their use as phosphodiesterase inhibitors
EP4568664A1 (en)	2023-04-07	2025-06-18	Terns Pharmaceuticals, Inc.	Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease
WO2025145091A1 (en)	2023-12-29	2025-07-03	Pfizer Inc.	Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000024745A1 (en) *	1998-10-23	2000-05-04	Pfizer Limited	PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
WO2002000600A1 (de) *	2000-06-27	2002-01-03	Qiagen Gmbh	Verwendung von kompositionen aus kationischen verbindungen und protonendonoren zur stabilisierung und/oder isolierung von nukleinsäuren in bzw. aus mikroorganismen - wie prokaryonten, pilzen, protozoen oder algen
WO2004096810A1 (en) *	2003-04-29	2004-11-11	Pfizer Limited	5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW370529B (en) *	1992-12-17	1999-09-21	Pfizer	Pyrazolopyrimidines
GB9823102D0 (en) *	1998-10-23	1998-12-16	Pfizer Ltd	Pharmaceutically active compounds
DE10031584A1 (de) *	2000-06-29	2002-01-10	Merck Patent Gmbh	5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
DE60237425D1 (de) *	2002-03-28	2010-10-07	Univerzita Palackeho V Olomouc	PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung

2003
- 2003-11-24 GB GBGB0327319.0A patent/GB0327319D0/en not_active Ceased
2004
- 2004-11-12 KR KR1020067010152A patent/KR100848216B1/ko not_active Expired - Fee Related
- 2004-11-12 DK DK04798876.1T patent/DK1689751T3/da active
- 2004-11-12 WO PCT/IB2004/003747 patent/WO2005049616A1/en not_active Ceased
- 2004-11-12 CN CN2004800345707A patent/CN1882591B/zh not_active Expired - Fee Related
- 2004-11-12 ME MEP-2010-203A patent/ME01216B/me unknown
- 2004-11-12 JP JP2006540647A patent/JP4056015B2/ja not_active Expired - Fee Related
- 2004-11-12 GE GEAP20049412A patent/GEP20084528B/en unknown
- 2004-11-12 ES ES04798876T patent/ES2351622T3/es not_active Expired - Lifetime
- 2004-11-12 SG SG200704860-6A patent/SG133614A1/en unknown
- 2004-11-12 EP EP04798876A patent/EP1689751B1/en not_active Expired - Lifetime
- 2004-11-12 CA CA002546987A patent/CA2546987C/en not_active Expired - Fee Related
- 2004-11-12 OA OA1200600166A patent/OA13289A/en unknown
- 2004-11-12 KR KR1020087009034A patent/KR100893999B1/ko not_active Expired - Fee Related
- 2004-11-12 MX MXPA06005914A patent/MXPA06005914A/es active IP Right Grant
- 2004-11-12 CN CN2008100859397A patent/CN101362764B/zh not_active Expired - Fee Related
- 2004-11-12 HR HR20100651T patent/HRP20100651T1/hr unknown
- 2004-11-12 RS RSP-2010/0534A patent/RS51556B/sr unknown
- 2004-11-12 PL PL04798876T patent/PL1689751T3/pl unknown
- 2004-11-12 CN CN200910151866A patent/CN101647802A/zh active Pending
- 2004-11-12 EA EA200600677A patent/EA011772B1/ru not_active IP Right Cessation
- 2004-11-12 CN CN200810085940XA patent/CN101362765B/zh not_active Expired - Fee Related
- 2004-11-12 SI SI200431562T patent/SI1689751T1/sl unknown
- 2004-11-12 AT AT04798876T patent/ATE485297T1/de active
- 2004-11-12 AP AP2006003591A patent/AP2227A/xx active
- 2004-11-12 PT PT04798876T patent/PT1689751E/pt unknown
- 2004-11-12 DE DE602004029705T patent/DE602004029705D1/de not_active Expired - Lifetime
- 2004-11-12 NZ NZ548097A patent/NZ548097A/en not_active IP Right Cessation
- 2004-11-12 BR BRPI0416869-0A patent/BRPI0416869A/pt not_active Application Discontinuation
- 2004-11-12 AU AU2004290643A patent/AU2004290643B2/en not_active Ceased
- 2004-11-22 PE PE2004001138A patent/PE20051061A1/es not_active Application Discontinuation
- 2004-11-22 MY MYPI20044834A patent/MY140872A/en unknown
- 2004-11-22 UY UY28625A patent/UY28625A1/es active IP Right Grant
- 2004-11-23 TW TW093136019A patent/TWI265031B/zh not_active IP Right Cessation
- 2004-11-23 AR ARP040104331A patent/AR046711A1/es not_active Application Discontinuation
- 2004-11-23 NL NL1027568A patent/NL1027568C2/nl not_active IP Right Cessation
- 2004-11-23 PA PA20048617701A patent/PA8617701A1/es unknown
- 2004-12-11 UA UAA200605669A patent/UA81994C2/uk unknown
2006
- 2006-04-10 ZA ZA200602899A patent/ZA200602899B/en unknown
- 2006-04-10 IS IS8406A patent/IS8406A/is unknown
- 2006-05-04 IL IL175433A patent/IL175433A/en not_active IP Right Cessation
- 2006-05-23 CR CR8416A patent/CR8416A/es unknown
- 2006-05-23 EC EC2006006580A patent/ECSP066580A/es unknown
- 2006-05-24 TN TNP2006000154A patent/TNSN06154A1/fr unknown
- 2006-05-24 MA MA29050A patent/MA28172A1/fr unknown
- 2006-06-23 NO NO20062950A patent/NO336526B1/no not_active IP Right Cessation
2010
- 2010-11-24 CY CY20101101062T patent/CY1110933T1/el unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000024745A1 (en) *	1998-10-23	2000-05-04	Pfizer Limited	PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
WO2002000600A1 (de) *	2000-06-27	2002-01-03	Qiagen Gmbh	Verwendung von kompositionen aus kationischen verbindungen und protonendonoren zur stabilisierung und/oder isolierung von nukleinsäuren in bzw. aus mikroorganismen - wie prokaryonten, pilzen, protozoen oder algen
WO2004096810A1 (en) *	2003-04-29	2004-11-11	Pfizer Limited	5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension

Also Published As

Publication number	Publication date
NO336526B1 (no)	2015-09-21
CN101362765B (zh)	2011-02-02
KR100893999B1 (ko)	2009-04-20
CN1882591B (zh)	2011-08-10
SI1689751T1 (sl)	2011-01-31
CY1110933T1 (el)	2015-06-10
EA011772B1 (ru)	2009-06-30
MY140872A (en)	2010-01-29
BRPI0416869A (pt)	2007-03-27
CA2546987C (en)	2009-05-12
CR8416A (es)	2006-11-15
PT1689751E (pt)	2010-11-29
AP2006003591A0 (en)	2006-04-30
ES2351622T3 (es)	2011-02-08
NZ548097A (en)	2008-12-24
UA81994C2 (en)	2008-02-25
MA28172A1 (fr)	2006-09-01
PL1689751T3 (pl)	2011-03-31
TNSN06154A1 (fr)	2007-11-15
ATE485297T1 (de)	2010-11-15
EP1689751B1 (en)	2010-10-20
UY28625A1 (es)	2005-06-30
IS8406A (is)	2006-04-10
RS51556B (sr)	2011-06-30
SG133614A1 (en)	2007-07-30
EP1689751A1 (en)	2006-08-16
CN101362764B (zh)	2011-04-20
HK1128917A1 (en)	2009-11-13
JP4056015B2 (ja)	2008-03-05
PA8617701A1 (es)	2005-08-04
DE602004029705D1 (de)	2010-12-02
IL175433A0 (en)	2006-09-05
NL1027568A1 (nl)	2005-05-26
PE20051061A1 (es)	2005-12-12
HRP20100651T1 (hr)	2011-01-31
ECSP066580A (es)	2006-12-20
KR20080052666A (ko)	2008-06-11
GEP20084528B (en)	2008-11-10
IL175433A (en)	2011-08-31
ZA200602899B (en)	2007-07-25
CN101362764A (zh)	2009-02-11
DK1689751T3 (da)	2011-01-17
KR100848216B1 (ko)	2008-07-24
WO2005049616A1 (en)	2005-06-02
CN1882591A (zh)	2006-12-20
NL1027568C2 (nl)	2005-11-30
MXPA06005914A (es)	2006-06-27
HK1099286A1 (en)	2007-08-10
TW200520758A (en)	2005-07-01
TWI265031B (en)	2006-11-01
EA200600677A1 (ru)	2006-12-29
WO2005049616A8 (en)	2006-06-01
AR046711A1 (es)	2005-12-21
AU2004290643A1 (en)	2005-06-02
GB0327319D0 (en)	2003-12-24
KR20070026334A (ko)	2007-03-08
OA13289A (en)	2007-01-31
CN101362765A (zh)	2009-02-11
CA2546987A1 (en)	2005-06-02
AU2004290643B2 (en)	2008-08-07
NO20062950L (no)	2006-08-23
ME01216B (me)	2013-03-20
JP2007512314A (ja)	2007-05-17
CN101647802A (zh)	2010-02-17

Publication	Publication Date	Title
AP2227A (en)	2011-03-29	5,7-diaminopyrazolo [4,3-d]pyrimidines with PDE-5 inhibiting activity.
IL182099A0 (en)	2007-07-24	Piperidinylamino-thieno[2,3-d] pyrimidine compounds
EP1599482A4 (en)	2008-10-01	PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
NO20040540L (no)	2004-02-05	4-amino-6-fenylpyrrolo[2,3-D]pyrimidinderivater.
AP2005003403A0 (en)	2005-12-31	Substituted pyrimidinones.
PL376916A1 (pl)	2006-01-09	Pochodne pirymido [4,5-d] pirymidyny o działaniu przeciwrakowym
AP2005003365A0 (en)	2005-09-30	Hiv inhibiting 1, 2, 4-triazines.
IL170680A0 (en)	2009-02-11	8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
IL164442A0 (en)	2005-12-18	Benzoxazinone-derived compounds, their preparationand use as medicaments
MXPA03007320A (es)	2003-12-04	Nuevos compuestos de pirimidina.
ZA200507192B (en)	2007-03-28	Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one derivatives
MXPA03007433A (es)	2003-11-18	Pirazolil pirimidinas.
ZA200501679B (en)	2005-09-06	Recreation range.
AP2157A (en)	2010-09-13	2-substituted pyrimidines.
PL358551A1 (en)	2004-08-09	5-aminoalkyl-pyrazolo[4,3-d]pyrimidines
AP2006003539A0 (en)	2006-04-30	5-halogeno-[1,2,4]triazolo[1,5-A] pyrimidines for combating animal pests.
MXPA03004498A (es)	2003-09-05	Uso de pirazolo (4,3-d)pirimidinas.
GB0323137D0 (en)	2003-11-05	2,4,6- Trisubstituted pyrimidines and their different uses
AP2006003496A0 (en)	2006-02-28	2-Substituted pyrimidines.
PL361915A1 (en)	2004-10-04	Substituted 3.4-dihydro-pyrido[1,2-a]pyrimidines
PL375417A1 (en)	2005-11-28	2,3-dihydro-isoindol-1-ones with mao-b inhibiting activity
TWI372760B (en)	2012-09-21	A pyrazolo[1,5-a]pyrimidine compound
LU91022B1 (en)	2004-11-10	Sektionaltor.
ZA200600471B (en)	2007-04-25	7-substituted 3-nitro-pyrazolo[1,5-A] pyrimidines
TJ431B (en)	2007-06-05	2-Brom-7-methil-5-oxo-5h-1,3,4-thyodyazol-(3,2-a)pyrimidin, has antibacterial activity